1

SARS-CoV-2 and endemic coronaviruses: Comparing symptom

presentation and severity of symptomatic illness among Nicaraguan

children

Aaron M Frutos[1], John Kubale[1], Guillermina Kuan[2], Sergio Ojeda[3], Nivea Vydiswaran[1], Nery

Sanchez[3], Miguel Plazaola[3], May Patel[1], Roger Lopez[3,4], Angel Balmaseda[3,4¶], Aubree Gordon[1*¶]

[1] Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor,

MI, USA

[2] Health Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua

[3] Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of

Health, Managua, Nicaragua.

[4] Sustainable Sciences Institute, Managua, Nicaragua.

*Corresponding author

E-mail: gordonal@umich.edu (AG)

¶ These authors contributed equally.

Abstract

It has been proposed that as SARS-CoV-2 transitions to endemicity, children will represent the greatest proportion of SARS-Co-V-2 infections as they currently do with endemic coronavirus infections. While SARS-CoV-2 infection severity is low for children, it is unclear if SARS-CoV-2 infections are distinct in symptom presentation, duration, and severity from endemic coronavirus infections in children. We compared symptom risk and duration of endemic human coronavirus (HCoV) infections from 2011-2016 with SARS-CoV-2 infections from March 2020-September 2021 in a Nicaraguan pediatric cohort. Blood samples were collected from study participants annually in February-April. Respiratory samples were collected from participants that met testing criteria. Blood samples collected in were tested for SARS-CoV-2 antibodies and a subset of 2011-2016 blood samples from four-year-old children were tested for endemic HCoV antibodies. Respiratory samples were tested for each of the endemic HCoVs from 2011-2016 and for SARS-CoV-2 from 2020-2021 via rt-PCR. By April 2021, 854 (49%) cohort participants were ELISA positive for SARS-CoV-2 antibodies. Most participants had antibodies against one alpha and one beta coronavirus by age four. We observed 595 symptomatic endemic HCoV infections from 2011-2016 and 121 symptomatic with SARS-CoV-2 infections from March 2020-September 2021. Symptom presentation of SARS-CoV-2 infection and endemic coronavirus infections were very similar, and SARS-CoV-2 symptomatic infections were as or less severe on average than endemic HCoV infections. This suggests that, for children, SARS-CoV-2 may be just another endemic coronavirus. However, questions about the impact of variants and the long-term effects of SARS-CoV-2 remain.

Introduction

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transitions to global

endemicity, there are many questions about how that will occur. Over time, children will

represent the greatest proportion of primary SARS-CoV-2 infections as adults gain immunity

from natural infection or vaccination. (1) It is well established that pediatric risk of severe illness

and death is much lower than that for adults. (2, 3) Differences in immune response between

adults and children likely provide children better protection against severe SARS-CoV-2

infections. (3-5) Previous research found no differences in severity between SARS-CoV-2

infections and influenza A and B among children. (6, 7) However, it is unknown if, in children,

SARS-CoV-2 infections are distinct in disease presentation and severity from endemic human

coronavirus (HCoV) infections.

As of January 2022, only the Pfizer vaccine (for those age 5 or older) and the Moderna

vaccine (for those 12 or older) are recommended by the World Health Organization's Strategic

Advisory Group of Experts (SAGE) for use in children and adolescents; multiple other vaccines,

including the Cuban Soberana 02 and Abdala, have been approved for use in children by

individual countries, including in Nicaragua.(8-10) If SARS-COV-2 infections are more severe,

routine pediatric vaccination will be necessary to reduce excess mortality and morbidity. If not,

vaccine-induced immunity should prevent severe disease while allowing for transmission to

facilitate frequent immune boosting. (1) To determine if SARS-CoV-2 infections have distinct

disease presentation from endemic HCoV infections in children, we compare symptomatic

63   SARS-CoV-2 and endemic HCoV infection symptomology and severity in a prospective,

64   community-based pediatric cohort in Managua, Nicaragua from 2011-2016 and 2020-2021

Methods

Institutional review boards at the Nicaraguan Ministry of Health and the University of

Michigan approved this study. Parents/guardians of participants provided written informed

consent and participants aged ≥6 years provided verbal assent. The Nicaraguan Pediatric

Influenza Cohort Study (NPICS) is a prospective cohort study that began in 2011 and continues

today. Children ages 0-14 years who live in District 2 of Managua, Nicaragua and within the

catchment area of Health Center Sócrates Flores Vivas were eligible to participate. Participants

live in a tropical, urban environment and are representative of children in the larger Managua

area. Participants included in this analysis were members of NPICS between 2011-2016 or

March 2020 to September 2021. School-aged children attended school throughout the study

period.

Study staff collected blood samples from each study participant between February and

April each year. To confirm our assumption that endemic HCoV infection rates are high in the

cohort, we tested a random subset of 100 blood samples from four-year-old's from 2011-2016;

using protocols for an enzyme-linked immunosorbent assay (ELISA) developed at Mount Sinai

(11), we tested samples for IgG antibody response to the spike protein for each of the four

endemic HCoVs (alpha: NL63, and 229E, beta: OC43 and HKU1). To confirm that SARS-CoV-

2 infections rates were also high, we tested the 2020 and 2021 blood samples in pairs for SARS-

CoV-2 IgG antibodies as described previously. If a 2020 annual sample was positive for SARS-

CoV-2, the child's 2019 annual sample was also run. Children that were positive in 2019 were

not considered SARS-CoV-2 positive. (12)

Parents/guardians agreed to bring participants to the health center at the first signs of

fever. Study personnel collected a respiratory swab from participants if they met the testing

criteria: feverishness for participants under two years old; measured fever/feverishness and

cough, sore throat, or rhinorrhea; severe respiratory symptoms such as apnea or chest indrawing;

hospitalization with respiratory symptoms or sepsis. NPICS testing criteria expanded in June

2020 to capture mild symptomatic SARS-CoV-2 cases; however, this analysis is limited to those

meeting the original testing criteria to ensure comparability. We used real-time reverse

transcription polymerase-chain reaction (RT-PCR) to test respiratory samples from 2011-2016

for each of the four endemic HCoV, influenza A and B, respiratory syncytial virus (RSV,

subtypes A and B), and human metapneumovirus (HMpV) and samples from March 2020-

September 2021 for SARS-CoV-2 and influenza. (13, 14)

Study clinicians record all participant symptoms, prescriptions, and diagnoses during

each clinic visit and subsequent medical appointments using standardized forms.

Parents/guardians report participant symptoms for each day since illness onset to study clinicians

at the initial and subsequent clinic visits until symptom resolution. We considered symptoms to

be associated with an infection if they occurred within 28 days of symptom onset. Study

parents/guardians reported on the following symptoms 2011-2016 and 2020-2021: feverishness,

cough, rhinorrhea, nasal congestion, loss of appetite, myalgia, arthralgia, and rapid breathing.

We considered participants who presented to the clinic with rapid breathing, rhonchi, indrawing,

wheezing, or shortness of breath as having abnormal breathing. We defined acute lower

respiratory infections (ALRI) as physician diagnosed cases of pneumonia, bronchiolitis,

bronchitis, or bronchial hyperreactivity or elevated respiratory rate based on age: ≥ 60

breaths/minute for < 2 months, ≥ 50 breaths/minute for 2-11 months, ≥ 40 breaths/minute for

12-59 months, ≥ 25 breaths/minute for ≥ 60 months (15). We also evaluated whether

participants with ALRI were prescribed antibiotics (amoxicillin, penicillin, other) within 28 days

of infection. Data collection forms for the above signs and symptoms were consistent between

2011-2016 and 2020-2021.

To compare risk of symptoms, we calculated symptom specific risk differences between

SARS-CoV-2 infections and endemic HCoV infections, overall and stratified by the following

age groups: 0-4, 5-9, and 10-14 years. We also stratified the results by sex and endemic HCoV

species. Using upset plots, we explored which signs/symptoms tended to present together. We

also assessed symptom duration by comparing the time between each specific symptom onset

and the last day participants presented with that symptom. We plotted symptom duration using

boxplots and compared the distribution of symptom duration between SARS-CoV-2 and

endemic HCoVs using the Mann Whitney U test.

We used SAS version 9.4 (SAS Institute Inc.) to calculate risk differences and ratios and

R version 4.1.0 to create figures and conduct all other analyses.

Results

There were 3,220 participants active in NPICS during the included years: 2,576 from

2011-2016 and 1,942 from March 2020-September 2021. On average, there were 1,792 active

participants per year. Our assumption was that detected symptomatic infections consist of only a

small proportion of total SARS-CoV-2 and endemic HCoV infections that occurred in the cohort

children. Specifically, of the 1,942 children in the cohort from March 2020-September 2021,

1,455 in 2020 and 1,743 in 2021 had a blood sample collected that was tested via ELISA for

SARS-CoV-2 antibodies. Only 23 (1.6%) tested positive for SARS-CoV-2 antibodies in 2020

while 854 (49%) tested positive in 2021 indicating that SARS-CoV-2 infections were very high

in the cohort. We found that 94% of our randomly selected subset of four-year-olds from 2011-

2016 had an antibody response to at least one alpha and one beta HCoV, confirming our

assumption of high endemic HCoV infection rates in the community. Antibody response

prevalence was highest for OC43 (99%) followed by HKU1 (86%), NL63 (83%), and then 229E

(74%) (Table 1).

Table 1: Endemic HCoVs ELISA Results, % Positive

	Total (n=100)
Alpha	94%
NL63	83%
229E	74%
Beta	100%
OC43	99%
HKU1	86%

Within this cohort we observed high infection rates of both endemic HCoVs and SARS-

CoV-2. That there were 595 RT-PCR+ symptomatic endemic HCoV infections from 2011-2016

and 121 RT-PCR+ symptomatic SARS-CoV-2 infections from March 2020- September 2021

again suggests that symptomatic cases represent only a small proportion of overall infections and

likely, the more severe infections. Most endemic HCoV, 432 (73%), and SARS-CoV-2, 59

(49%), infections occurred in participants <5 years. Fever, cough, rhinorrhea, and congestion

were the most common symptoms for both endemic HCoVs and SARS-CoV-2 symptomatic

infections. Cough, rhinorrhea, and abnormal breathing was more common among endemic

HCoV infections while measured fever and headache was more common among SARS-CoV-2

infections. Among SARS-CoV-2 symptomatic infections, 4 (3%) were acute lower respiratory

infections compared to 98 (16%) endemic HCoV cases (p=<0.0001; Table 2). Among those with

ALRI, there was not a difference in antibiotic prescription between SARS-CoV-2 and endemic

HCoV infections.

Table 2: Study Participants and Symptom Prevalence

	Endemic HCoVs (n=595)	SARS-CoV-2 (n=121)	p-value*
Age Group (%)			<.0001
0-4	432 (73)	59 (49)	
5-9	110 (18)	29 (24)	
10-14	53 (9)	33 (27)	
Symptoms (%)			
Measured fever	272 (46)	68 (56)	0.035
Cough	524 (88)	85 (70)	<0.001
Rhinorrhea	505 (85)	93 (77)	0.030
Congestion	276 (46)	45 (37)	0.064

Sore throat	145 (24)	36 (30)	0.221
Headache	81 (14)	38 (31)	<0.001
Loss of appetite	142 (24)	31 (26)	0.681
Diarrhea	64 (11)	14 (12)	0.793
Hospitalized	23 (4)	6 (5)	0.578
Abnormal breathing	108 (18)	9 (7)	0.004
Acute lower respiratory infection	107 (18)	7 (6)	<0.001
ALRI and prescribed antibiotics†	79 (74)	6 (85)	0.484

157
158   * p-value from chi-square test
159   † % represents % of ALRI cases
160

Because the age distribution varied between endemic HCoVs and SARS-CoV-2, with a

greater proportion of infections occurring in older children with SARS-CoV-2, we examined

signs and symptoms by age group. Across age groups, participants with symptomatic endemic

HCoV infections displayed greater risk of cough compared to those with symptomatic SARS-

CoV-2 infections. Among participants aged <5 years, symptomatic endemic HCoV infections

showed greater risk of rhinorrhea, congestion, abnormal breathing, and ALRI than symptomatic

SARS-CoV-2 infections, while SARS-CoV-2 exhibited greater risk of measured fever (Fig 1,

Table 3). Notably, among those under 5, symptomatic endemic HCoV infection was associated

with greater risk of ALRI even after excluding participants that also tested positive for influenza

A, influenza B, RSV, or HMpV. We observed no difference in risk hospitalization between

SARS-CoV-2 and endemic HCoV symptomatic infections in each age group. These results were

consistent after stratifying by sex (S1-S2 Fig), or endemic HCoV species (S3-S6 Fig).

Fig 1: Symptom Risk Difference between Endemic HCoVs and SARS-CoV-2.

A: All participants. B: Ages 0-4 years. C: Ages 5-9 years. D Ages: 10-14 years.

 Table 3: Symptom Risk between Endemic HCoV and SARS-CoV-2 by Age Group

0-4				
	Endemic HCoVs (%)	SARS-CoV-2 (%)	Risk Difference (95% CI)	Risk Ratio (95% CI)
Measured fever	218 (50)	44 (75)	-0.24 (-0.36, -0.12)	0.68 (0.57, 0.81)
Cough	382 (88)	42 (71)	0.17 (0.05, 0.29)	1.24 (1.05, 1.47)
Rhinorrhea	378 (88)	42 (71)	0.16 (0.04, 0.28)	1.23 (1.04, 1.45)
Congestion	241 (50)	21 (36)	0.14 (0.09, 0.27)	1.39 (0.97, 1.99)
Sore throat	66 (15)	6 (10)	0.05 (-0.03, 0.14)	1.50 (0.68, 3.31)
Headache	23 (5)	4 (7)	-0.01 (-0.08, 0.05)	0.79 (0.28, 2.19)
Loss of appetite	116 (27)	19 (32)	-0.05 (-0.18, 0.07)	0.83 (0.56, 1.25)
Diarrhea	58 (13)	9 (15)	-0.02 (-0.12, 0.08)	0.88 (0.46. 1.68)
Hospitalized	17 (4)	4 (7)	-0.03 (-0.10, 0.04)	0.58 (0.20, 1.67)
Abnormal breathing	95 (22)	4 (7)	0.15 (0.08, 0.23)	3.24 (1.24, 8.49)
ALRI	89 (21)	4 (7)	0.14 (0.6, 0.21)	3.04 (1.16, 7.97)
ALRI[*]	69 (19)	4 (7)	0.12 (0.04,0.19)	3.74 (1.04, 7.22)
5-9				
	Endemic HCoVs (%)	SARS-CoV-2 (%)	Risk Difference (95% CI)	Risk Ratio (95% CI)
Measured fever	39 (35)	12 (41)	-0.06 (-0.26, 0.14)	0.86 (0.52, 1.41)
Cough	99 (90)	21 (72)	0.18 (000, 0.35)	1.24 (0.98, 1.57)
Rhinorrhea	87 (79)	25 (86)	-0.07 (-0.22, 0.08)	0.92 (0.77, 1.09)
Congestion	42 (38)	14 (48)	-0.10 (-0.10, 0.30)	0.79 (0.51, 1.23)
Sore throat	52 (47)	12 (41)	0.06 (-0.14, 0.26)	1.14 (0.71, 1.84)
Headache	35 (32)	14 (48)	-0.16 (-0.37, 0.04)	0.66 (0.41, 1.04)
Loss of appetite	19 (17)	7 (24)	-0.07 (-0.24, 0.10)	0.72 (0.33, 1.54)
Diarrhea	4 (4)	3 (10)	-0.07 (-0.18, 0.05)	0.35 (0.08, 1.48)
Hospitalized	5 (5)	2 (7)	-0.02 (-0.12, 0.08)	0.66 (0.13, 3.23)
Abnormal breathing	10 (9)	2 (7)	0.02 (-0.08, 0.12)	1.32 (0.31, 5.69)
ALRI	15 (14)	3 (10)	0.03 (-0.10, 0.16)	1.32 (0.41, 4.25)
ALRI[*]	12 (13)	3 (10)	0.03 (-0.10, 0.16)	1.26 (0.38, 4.16)
10-14				
	Endemic HCoVs (%)	SARS-CoV-2 (%)	Risk Difference (95% CI)	Risk Ratio (95% CI)
Measured fever	15 (28)	12 (36)	-0.08 (-0.28, 0.12)	0.78 (0.42, 1.45)
Cough	43 (81)	22 (67)	0.14 (-0.05, 0.34)	1.22 (0.93, 1.60)
Rhinorrhea	40 (75)	26 (79)	-0.03 (-0.21, 0.15)	0.96 (0.76, 1.21)

Congestion	20 (38)	10 (30)	0.07 (-0.13, 0.28)	1.25 (0.67, 2.32)
Sore throat	27 (51)	18 (55)	-0.04 (-0.25, 0.18)	0.93 (0.62, 1.41)
Headache	23 (43)	20 (61)	-0.17 (-0.39, 0.04)	0.25 (0.47, 1.08)
Loss of appetite	7 (13)	5 (15)	-0.02 (-0.17, 0.13)	0.87 (0.30, 2.52)
Diarrhea	2 (4)	2 (6)	-0.02 (-0.12, 0.07)	0.62 (0.09, 4.21)
Hospitalized	1 (2)	0	0.02 (-0.02, 0.06)	-
Abnormal breathing	3 (6)	3 (9)	-0.03 (-0.15, 0.08)	0.62 (0.13, 2.90)
ALRI	3 (4)	0	0.06 (-0.01, 0.12)	-
ALRI*	3 (6)	0	0.06 (-0.01, 0.13)	-

*Excluding influenza A, influenza B, RSV, and HMpV coinfections

For both endemic HCoVs and SARS-CoV-2, we found that cough, rhinorrhea, and sore

throat frequently presented together. Loss of appetite appeared in common symptom groupings

for endemic HCoVs, while headache was part of more common groupings for SARS-CoV-2 (Fig

2). We did find that among participants aged 0-4 years loss of appetite lasted longer and among

participants aged 5-9 and 10-14, cough lasted longer for SARS-CoV-2 infections., (Fig 3, Table

4).

Fig 2. Comparison of Common Symptom Groupings between Symptomatic Endemic

HCoVs and SARS-CoV-2 Infections.

A

B

191 A: Upset plot of symptom groupings for symptomatic SARS-CoV-2 infections. B. Upset plot of

192 symptom groupings for symptomatic endemic HCoV infections.

193 **Fig 3. Comparison of Symptom Duration between Symptomatic Endemic HCoVs and**

194 **SARS-CoV-2 Infections.**

198   **Table 4: Symptom Duration Comparison: SARS-CoV-2, Endemic HCoVs**

Mean Symptom Duration in Days (SD)		
All		
SARS-CoV-2	**Endemic HCoVs**	**p-value***
Feverish	3.8 (6.1)	3.8 (7.1)	0.137
Cough	6.7 (6.4)	5.5 (8.0)	0.003
Rhinorrhea	4.4 (5.7)	4.6 (7.3)	0.354
Congestion	2.8 (4.7)	2.8 (5.6)	0.997
Loss of appetite	2.2 (2.8)	1.4 (3.4)	0.032

0-4		
	SARS-CoV-2	**Endemic HCoVs**	**p-value***
Feverish	5.3 (7.3)	4.4 (7.6)	0.069
Cough	6.4 (6.0)	6.4 (8.6)	0.178
Rhinorrhea	5.1 (5.8)	5.4 (7.9)	0.278
Congestion	2.6 (3.8)	3.0 (5.8)	0.875
Loss of appetite	2.5 (3.0)	1.6 (3.7)	0.039

5-9		
	SARS-CoV-2	**Endemic HCoVs**	**p-value***
Feverish	2.0 (4.0)	2.4 (5.4)	0.397
Cough	8.1 (7.5)	3.2 (5.8)	0.002
Rhinorrhea	3.9 (5.5)	2.3 (4.7)	0.125
Congestion	3.4 (6.3)	1.9 (4.4)	0.690
Loss of appetite	2.1 (2.6)	1.0 (1.2)	0.352

10-14		
	SARS-CoV-2	**Endemic HCoVs**	**p-value***
Feverish	2.6 (4.7)	1.7 (3.8)	0.434
Cough	6.0 (6.2)	2.3 (4.3)	0.015
Rhinorrhea	3.5 (6.0)	2.2 (5.0)	0.440
Congestion	2.5 (3.9)	2.6 (5.6)	0.479
Loss of appetite	1.2 (2.2)	0.4 (0.8)	0.698

*From Mann-Whitney U test

To assess the potential impact of variants on symptoms, we compared symptoms for

SARS-CoV-2 infections from 2020 prior to the global emergence of variants and 2021 when

delta, gamma, and lambda strains circulated in the cohort area and found no difference in

presentation by year. Feverishness, rhinorrhea, cough, headache, and sore throat where the most

common symptoms for SARS-CoV-2 cases in both 2020 and 2021. (Fig 4). All observed cases

of ALRI associated with SARS-CoV-2 occurred in 2020. However, we did find that rhinorrhea

lasted longer in SARS-CoV-2 cases from 2021 compared to 2020 (Table 5).

Fig 4. Comparison of Common Symptom Groupings between Symptomatic SARS-CoV-2

Infections in 2020 and 2021

A: 2020. B. 2021

Table 5: Symptom Duration Comparison: SARS-CoV-2 by Year

	Mean Symptom Duration in Days (SD)		p-value*
	2020	**2021**	
Feverish	4.1 (7.4)	3.6 (5.0)	0.129
Cough	6.8 (8.0)	6.7 (5.5)	0.382
Rhinorrhea	2.7 (5.0)	5.4 (6.0)	0.004
Congestion	1.6 (2.3)	3.3 (5.2)	0.378
Loss of appetite	3.5 (3.8)	1.6 (1.9)	0.172

*From Mann-Whitney U test

Discussion

This is, to our knowledge, the first study that assesses differences in symptom presentation, duration, and severity between SARS-CoV-2 and endemic HCoV symptomatic infections among children Understanding how SARS-CoV-2 infections compare to endemic HCoV infections is important as SARS-CoV-2 becomes endemic. Other studies have evaluated symptom presentation for endemic HCoV and SARS-CoV-2 infections in children separately. (2, 16-20) This work, however, compares medically attended illnesses associated with endemic HCoV and SARS-CoV-2 infections in a large, prospective cohort of children with high infection rates.

In this pediatric cohort, we found that with 854 (49%) participants tested positive for SARS-CoV-2 antibodies in 2021 with only 121 PCR confirmed infections that met the original testing criteria. These results are consistent with results from our community-based household cohort study in the same setting. (12) We also found that most participants had at least one alpha and one beta endemic HCoV infection by age four suggesting that in this cohort, participants

230   have had at least two endemic HCoV exposures by the age of four. This is similar a previous

231   study that showed that by age six, most children have had infections with each of the four

232   endemic HCoVs with a majority being asymptomatic infections. (21) Thus for SARS-CoV-2 and

233   endemic HCoV, symptomatic infections also represent only a small proportion of all pediatric

234   infections.

235   Comparing these symptomatic infections, we found that pediatric disease presentation is

very similar between endemic HCoVs and SARS-CoV-2, with each frequently presenting with

"common cold" symptoms. Consistent with other studies, we found differences in symptom

presentation by age; this may be, perhaps, because older children have had more endemic HCoV

exposures (2, 4, 16, 17, 22). We also found great variability in symptom duration for SARS-

CoV-2 and endemic HCoV infections; symptoms from endemic HCoV and SARS-CoV-2

infections lasted anywhere from 1 day to more than 28. (20) There was a difference in duration

of loss of appetite for the youngest participants and cough for those aged 5-14 years suggesting

that some symptoms may last longer for SARS-CoV-2 infections. We also found a difference in

rhinorrhea duration between SARS-CoV-2 infections in 2020 and 2021, suggesting that SARS-

CoV-2 variants may increase symptom duration among children.

246   Across age groups, risk of ALRI associated with SARS-CoV-2 was the same or lower

compared to ALRI associated with endemic HCoV infection. Even when excluding endemic

HCoV co-infections with pathogens commonly associated with increased risk of ALRI, the

conclusions did not change. (16, 18) These results show that, for children, the risk of ALRI and

severe illness from SARS-CoV-2 infections is comparable to the risk from endemic HCoV

infections at the community level.

The main strength of this community-based study is its size and duration. Consistent viral

surveillance and symptom evaluation within the same population allow for year-to-year

comparisons and facilitates our comparisons of endemic HCoVs and SARS-CoV-2. The high

number of participants under the age of five (about 36% of participants during these years),

allows us to evaluate SARS-CoV-2 in an age group with little representation in current literature.

Additionally, this cohort was already well established when SARS-CoV-2 began circulating in

Nicaragua allowing us to quickly incorporate questions regarding its effects on this population.

However, this study does have some limitations. First, using data from this community-

based cohort study we were not powered to detect the most severe manifestations of SARS-CoV-

2 including death or Multisystem Inflammatory Syndrome in Children (MIS-C) and other rare

outcomes. (23, 24) Second, our analysis did not include genetic sequencing preventing us from

assessing the importance of variants in presentation and severity of SARS-CoV-2 illness. We did

compare SARS-CoV-2 symptom presentation, severity, and duration by year and found little or

no difference. Additionally, due to the low levels of circulation at the time, SARS-CoV-2

infections were only evaluated for influenza co-infections. We expect that RSV, and HMpV

coinfections would also be associated with increased risk of ALRI for SARS-CoV-2; excluding

such SARS-CoV-2 coinfections from the ALRI risk comparison would not change our findings.

Finally, while our study does not evaluate very mild or asymptomatic illness for endemic

HCoVs, our results were consistent with other research, showing that childhood HCoVs are

ubiquitous and that symptomatic cases represent only a small proportion of infections, as with

SARS-CoV-2. (21)

In this study, we observed that symptomatic SARS-CoV-2 infections at the community

level are very similar to symptomatic endemic HCoV infections in symptom presentation.

Among children in a tropical, urban setting with a high SARS-CoV-2 infection rate,

symptomatic SARS-CoV-2 infections are on average as or less severe as endemic HCoV

infections. These findings support the hypothesis that SARS-CoV-2 may be like another endemic

HCoV for children—most children will be asymptomatic with rare cases of severe symptomatic

illness. This does not mean SARS-CoV-2 in children is not important. There are many unknowns

about the long-term effects and impact of repeat infections among children. (1) Increased

transmissibility of emerging variants is also a cause for concern, as it will lead to increased

frequency of severe manifestations. Future mutations in the virus needed to be monitored as they

may also increase illness severity in children. Despite relatively low risk of severe illness among

children, pediatric vaccination that mirrors natural induced immunity against SARS-CoV-2

would further lower individual risk and reduce the number of severe cases and deaths due to

SARS-CoV-2.

References

289 1.   Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of
290 COVID-19 to endemicity. Science. 2021;371(6530):741-5.
291 2.   Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among
292 Children in China. Pediatrics. 2020;145(6).

293 3. Do LAH, Anderson J, Mulholland EK, Licciardi PV. Can data from paediatric cohorts
294 solve the COVID-19 puzzle? PLoS Pathog. 2020;16(9):e1008798.
295 4. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why
296 Children Fare Better than Adults? Indian J Pediatr. 2020;87(7):537-46.
297 5. Khan T, Rahman M, Ali FA, Huang SSY, Ata M, Zhang Q, et al. Distinct antibody
298 repertoires against endemic human coronaviruses in children and adults. JCI Insight. 2021;6(4).
299 6. Siddiqui M, Gultekingil A, Bakirci O, Uslu N, Baskin E. Comparison of clinical features
300 and laboratory findings of coronavirus disease 2019 and influenza A and B infections in
301 children: a single-center study. Clin Exp Pediatr. 2021.
302 7. Pokorska-Spiewak M, Talarek E, Popielska J, Nowicka K, Oldakowska A, Zawadka K, et
303 al. Comparison of clinical severity and epidemiological spectrum between coronavirus disease
304 2019 and influenza in children. Sci Rep. 2021;11(1):5760.
305 8. COVID-19 advice for the public: Getting vaccinated World Health Organization: World
306 Health Organization; 2022 [Available from: https://www.who.int/emergencies/diseases/novel-
307 coronavirus-2019/covid-19-vaccines/advice.
308 9. Nicaragua to Immunize the Child Population With Cuban Vaccines teleSUR: teleSUR;
309 2021 [Available from: https://www.telesurenglish.net/news/Nicaragua-to-Immunize-the-Child-
310 Population-With-Cuban-Vaccines-20211003-0002.html.
311 10. Reardon S. Cuba's bet on home-grown COVID vaccines is paying off. Nature.
312 2021;600(7887):15-6.
313 11. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al.
314 SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen
315 Production, and Test Setup. Curr Protoc Microbiol. 2020;57(1):e100.
316 12. Maier HE, Kuan G, Saborio S, Bustos Carrillo FA, Plazaola M, Barilla C, et al. Clinical
317 spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. Clin Infect
318 Dis. 2021.
319 13. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis
320 of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem.
321 2020;66(4):549-55.
322 14. Real-Time RT-PCR Assays for Non-Influenza Respiratory Viruses. In: Diseases NCfIaR,
323 editor.: Centers for Disease Control and Prevention; 2015. p. 1-16.
324 15. WHO Regional Office for Europe guidance for sentinel influenza surveillance in humans:
325 May 2011 Edition. Copenhagen, Denmark: The Regional Office for Europe of the World Health
326 Organization; 2011.
327 16. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics
328 and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an
329 Immunocompromised State. J Pediatric Infect Dis Soc. 2019;8(1):21-8.
330 17. Varghese L, Zachariah P, Vargas C, LaRussa P, Demmer RT, Furuya YE, et al.
331 Epidemiology and Clinical Features of Human Coronaviruses in the Pediatric Population. J
332 Pediatric Infect Dis Soc. 2018;7(2):151-8.

18.   de Koff EM, van Houten MA, Sanders EAM, Bogaert D. Severity of Respiratory
Infections With Seasonal Coronavirus Is Associated With Viral and Bacterial Coinfections.
Pediatr Infect Dis J. 2020.
19.   Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE. Epidemiology and clinical
presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3
years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48(8):2940-7.
20.   Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness
duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2.
Lancet Child Adolesc Health. 2021.
21.   Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute
respiratory syndrome human coronaviruses takes place during childhood. BMC Infect Dis.
2013;13:433.
22.   Ogimi C, Kim YJ, Martin ET, Huh HJ, Chiu CH, Englund JA. What's New With the Old
Coronaviruses? J Pediatric Infect Dis Soc. 2020;9(2):210-7.
23.   Children and COVID-19: State-Level Data Report. American Academy of Pediatrics

2021 August 12, 2021.
24.   Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al.
Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected
With SARS-CoV-2. JAMA Netw Open. 2021;4(6):e2116420.

Supporting information

 S1 Fig. Symptom Risk Difference between Endemic HCoVs and SARS-CoV-2 for Females.

358   A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14.

359   **S2 Fig. Symptom Risk Difference between Endemic HCoVs and SARS-CoV-2 for Males.**

361   A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14.

 S3 Fig. Symptom Risk Difference NL63 and SARS-CoV-2.

364   A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14.

    S4 Fig. Symptom Risk Difference between 229E and SARS-CoV-2.

367   A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14.

 S5 Fig. Symptom Risk Difference between OC43 and SARS-CoV-2.

370   A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14.

371   **S6 Fig. Symptom Risk Difference between HKU1 and SARS-CoV-2.**

373   A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14.